ArticleCancer epidemiology2026
Incidence and mortality trends after introduction of lung cancer screening in a community-based healthcare system.
Article in Cancer epidemiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundLung cancer screening (LCS) enables early cancer detection but raises concerns about overdiagnosis, particularly in community-based LCS settings where evidence remains limited. This study examined trends in lung cancer incidence and mortality following the introduction of LCS in a community-based setting and used these trends to assess the potential of LCS-associated overdiagnosis.
methodsThis retrospective study leveraged data and outcomes from the Kaiser Permanente Colorado (KPCO) LCS program between 2014 and 2023. Trends in lung cancer incidence and mortality were assessed by annual percent change (APC). Excess incidence was estimated by comparing post-LCS early-stage lung cancer incidence with pre-LCS program implementation and predicted incidence and expressed as counts and percentage of lung cancers.
resultsAmong 1006 incident lung cancers, 619 (62%) were early stage, 367 (37%) were late stage, and 20 (2%) had unknown stage; 198 lung cancer deaths were identified. Early-stage incidence increased (APC, 4.9%; 95% confidence interval (CI), -1.6-1.8%), late-stage incidence decreased (APC, -5.2%; 95% CI, -9.8% to -0.3%) and mortality decreased (APC, -6.0%, 95% CI, -12.3-0.8). Excess incidence suggests that 11.3%-35.9% of early-stage lung cancer cases could represent potential overdiagnosis, with only a portion of these reflecting true overdiagnosis.
conclusionWe observed patterns consistent with a maturing LCS screening program including a non-significant increase in early-stage detection, significant reduction in late-stage disease, and a non-significant decline in lung cancer-specific mortality. These findings provide an important starting point for understanding the impact of LCS on the distribution of stage in community-based screening programs. Continued monitoring of lung cancer incidence and mortality remains essential to refine estimates and evaluate their implications for healthcare resources, survivorship care, and the net benefit of screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.